Drug Profile
SWT 01100
Alternative Names: SWT 01.100Latest Information Update: 02 Jun 2005
Price :
$50
*
At a glance
- Originator SWITCH Biotech (CEASED)
- Class Antipsoriatics
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 01 Mar 2005 Discontinued - Phase-II for Psoriasis in Germany (Topical)
- 01 Mar 2005 SWITCH Biotech has closed down
- 22 Mar 2004 Phase-II clinical trials in Psoriasis in Germany (Topical)